---
title: "Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296487429.md"
description: "Turn Therapeutics reported peer-reviewed preclinical results for GX-03 in a mouse model of dermatitis. The study showed that GX-03 pretreatment reduced inflammatory signaling and itch, resulting in significantly less severe dermatitis compared to untreated controls. These findings support a prevention-oriented positioning for GX-03 in treating inflammatory skin diseases."
datetime: "2026-08-20T12:03:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296487429.md)
  - [en](https://longbridge.com/en/news/296487429.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296487429.md)
generator: "portal-rs"
---

# Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%

-   Turn Therapeutics reported newly published, peer-reviewed preclinical results for GX-03 in a mouse model of dermatitis-like inflammation. \* Findings were already presented via publication in Life, not flagged for a future medical meeting. \* GX-03 pretreatment reduced inflammatory signaling tied to skin inflammation and itch, producing a selective effect rather than broad immune suppression. \* Animals receiving GX-03 developed materially less severe dermatitis than untreated controls, supporting a prevention-oriented positioning in inflammatory skin disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260820905760) on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [TTRX.US](https://longbridge.com/en/quote/TTRX.US.md)

## Related News & Research

- [AbbVie Completes Acquisition of Apogee Therapeutics | ABBV Stock News](https://longbridge.com/en/news/297915640.md)
- [14:52 ETLe Super MOXI® de Sciton inaugure une nouvelle ère dans la revitalisation de la peau, de la tête aux pieds](https://longbridge.com/en/news/297687935.md)
- [Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study](https://longbridge.com/en/news/297800772.md)
- [08:53 ETCeraVe Takes a Skin-Barrier First Approach to Aging with New Super Boost Serum To Fight 5 Signs of Aging](https://longbridge.com/en/news/297789621.md)
- [17:53 ETActivatedYou's Essential Skin Food Wins Collagen Product of the Year at the 2026 Mindful Awards](https://longbridge.com/en/news/297565530.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**